The company has completed the patient enrolment in the clinical study of ASC22 (1mg/kg, SC, q4w) + Chidamide (10mg, BIW) in 15 HIV-infected patients. The study focuses is to evaluating the efficacy of ASC22 + Chidamide on the viral reservoirs of latently infected cells
The results showed that HIV latency was reversed in the clinical study by blocking the PD-1/PD-L1 pathway & reinforced the case for combining PD-1/PD-L1 Ab with other therapies to lower the HIV reservoir of latently infected cells
ASC22 is designed to restore virus-specific immune responses for chronic viral inf. Chidamide is the selective HDACi targeting subtype 1, 2, 3 of class I & subtypes 10 of class IIb HDAC with a mechanism against epigenetic abnormality
Ref: PRNewswire| Image: Ascletis Pharma
